The Global Fund works with a diverse group of pharmaceutical suppliers, many of whom also manufacture specialized essential medicines. By leveraging our position as one of the largest buyers of ARVs & ANTM in the global health market we establish framework agreements and negotiate references prices for several key, yet often low-volume, essential medicines recommended by the World Health Organization. These include medicines recommended for the prevention of opportunistic infections and treatments for hepatitis B, hepatitis C, cryptococcal disease and Kaposi’s sarcoma.
The Global Fund’s Market Shaping Strategy guides our efforts to increase access to quality-assured products at affordable and sustainable pricing to help reach patients most in need. The catalogue of essential medicines are available through the Pooled Procurement Mechanism on our online purchasing platform, wambo.org.